HZNP Horizon Therapeutics Public Limited Company

78.72
-0.19  -0%
Previous Close 78.91
Open 79.1
52 Week Low 23.81
52 Week High 86.67
Market Cap $17,374,297,970
Shares 220,710,086
Float 217,844,380
Enterprise Value $16,635,214,969
Volume 1,414,539
Av. Daily Volume 2,789,557
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Krystexxa with Methotrexate - MIRROR RCT
Gout
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
HZN-825
Idiopathic pulmonary fibrosis (IPF)
Phase 2b
Phase 2b
Phase 2b trial to be initiated mid-2021.
Teprotumumab
Thyroid Eye Disease (TED)
Approved
Approved
FDA Approval announced January 21, 2020.
ACTIMMUNE
Friedreich's Ataxia (FA)
Phase 3
Phase 3
Phase 3 data released December 8, 2016 - primary endpoint not met.

Latest News

  1. - Company to present at 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021 at 11:40 a.m. ET -

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced updates on its 2020 financial results, TEPEZZA supply and new KRYSTEXXA trials.

    "Amid the most challenging environment we have ever faced, we had a record year of performance, exceeding our full-year 2020 net sales and adjusted EBITDA guidance, driven by the significant outperformance of TEPEZZA and the strong second-half performance of KRYSTEXXA," said Tim Walbert, chairman, president and chief executive officer, Horizon. "We delivered exceptional shareholder value while expanding our pipeline, with six programs expected to begin this year, including two new KRYSTEXXA programs…

    - Company to present at 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021 at 11:40 a.m. ET -

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced updates on its 2020 financial results, TEPEZZA supply and new KRYSTEXXA trials.

    "Amid the most challenging environment we have ever faced, we had a record year of performance, exceeding our full-year 2020 net sales and adjusted EBITDA guidance, driven by the significant outperformance of TEPEZZA and the strong second-half performance of KRYSTEXXA," said Tim Walbert, chairman, president and chief executive officer, Horizon. "We delivered exceptional shareholder value while expanding our pipeline, with six programs expected to begin this year, including two new KRYSTEXXA programs. Additionally, we successfully completed the first increased scale TEPEZZA lot and we are on track to submit the resultant data to the FDA by the end of this month."

    Full-Year 2020 Preliminary Financial Results (unaudited)

    • Full-year 2020 net sales exceeded the high end of the Company's guidance range of $2.12 billion to $2.14 billion; exceeding the high end of this guidance range represents year-over-year growth of more than 65 percent.
    • Full-year 2020 adjusted EBITDA exceeded the high end of the Company's guidance range of $920 million to $940 million; exceeding the high end of this guidance range represents year-over-year growth of more than 95 percent and an adjusted EBITDA margin expansion of more than 700 basis points compared to 2019.
    • The outperformance was driven by strong net sales from its two key growth drivers, TEPEZZA, its biologic for the treatment of Thyroid Eye Disease (TED), and KRYSTEXXA, its biologic for the treatment of uncontrolled gout (chronic gout refractory to conventional therapy), as well as continued growth of its Rare Disease Business Unit.
    • TEPEZZA full-year 2020 net sales exceeded $800 million, with double-digit sequential growth in the fourth quarter of 2020.
    • KRYSTEXXA full-year 2020 net sales exceeded $400 million, with double-digit sequential growth in the fourth quarter of 2020.
    • Cash and cash equivalents at Dec. 31, 2020 were $2.08 billion and gross leverage was less than 1.1 times.

    These preliminary financial results are unaudited and subject to adjustment. Horizon will report its final fourth quarter and full-year 2020 financial results in February.

    TEPEZZA Supply Update

    As previously announced on Dec. 17, 2020 the Company expects a short-term disruption in TEPEZZA supply as a result of government-mandated COVID-19 vaccine production orders related to Operation Warp Speed that dramatically restricted capacity available for TEPEZZA at its drug product contract manufacturer, Catalent. The Company anticipates that this drug supply shortage could last through the first quarter. The length of the TEPEZZA supply disruption will depend on whether future manufacturing slots are successfully completed as well as decisions by the U.S. Food and Drug Administration (FDA) regarding the increased scale manufacturing process of TEPEZZA.

    The Company has made significant progress with TEPEZZA drug product supply over the last several weeks, successfully completing its first manufacturing lot at increased scale and beginning its second manufacturing lot at increased scale. The Company continues to expect to submit data this month from the first increased scale drug product manufacturing lot to the FDA for its review and approval.

    Pipeline Update

    The Company also announced two new KRYSTEXXA development programs it expects to begin in 2021, bringing the total number of programs in its pipeline to 14.

    • KRYSTEXXA monthly dosing trial: This open-label trial will evaluate a monthly dosing regimen of KRYSTEXXA, with methotrexate, to treat people with uncontrolled gout. The current dosing schedule for KRYSTEXXA is every other week. The goal of the trial is to explore whether a monthly dosing regimen can provide similar outcomes as the current dosing schedule.
    • KRYSTEXXA retreatment trial: This open-label trial will evaluate KRYSTEXXA, with methotrexate, in patients who have previously failed KRYSTEXXA. The goal of the trial is to evaluate whether patients can benefit from KRYSTEXXA, with methotrexate, after developing an immune response to KRYSTEXXA when taken alone. Patients who have previously failed KRYSTEXXA have limited options available to address their uncontrolled gout.

    Presentation Information

    Mr. Walbert will present at the J.P. Morgan Healthcare Conference at 11:40 a.m. ET on Jan. 12, 2021. The conference presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizontherapeutics.com. A replay of the webcast will be available following the event.

    About KRYSTEXXA

    INDICATIONS AND USAGE

    KRYSTEXXA (pegloticase injection) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.

    Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

    Important Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.

    IMPORTANT SAFETY INFORMATION

    WARNING: ANAPHYLAXIS AND INFUSION REACTIONS

    Anaphylaxis and infusion reactions have been reported to occur during and after administration of KRYSTEXXA. Anaphylaxis may occur with any infusion, including a first infusion and generally manifests within 2 hours of the infusion. However, delayed-type hypersensitivity reactions have also been reported. KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and infusion reactions. Patients should be premedicated with antihistamines and corticosteroids. Patients should be closely monitored for an appropriate period of time for anaphylaxis after administration of KRYSTEXXA. Serum uric acid levels should be monitored prior to infusions, and healthcare providers should consider discontinuing treatment if levels increase to above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are observed.

    The risk of anaphylaxis and infusion reactions is higher in patients who have lost therapeutic response.

    Concomitant use of KRYSTEXXA and oral urate-lowering agents may blunt the rise of sUA levels. Patients should discontinue oral urate-lowering agents and not institute therapy with oral urate-lowering agents while taking KRYSTEXXA.

    In the event of anaphylaxis or infusion reaction, the infusion should be slowed, or stopped and restarted at a slower rate.

    Patients should be informed of the symptoms and signs of anaphylaxis and instructed to seek immediate medical care should anaphylaxis occur after discharge from the healthcare setting.

    CONTRAINDICATIONS: G6PD DEFICIENCY ASSOCIATED HEMOLYSIS AND METHEMOGLOBINEMIA

    Patients should be screened for G6PD deficiency prior to starting KRYSTEXXA. Hemolysis and methemoglobinemia have been reported with KRYSTEXXA in patients with G6PD deficiency. KRYSTEXXA should not be administered to these patients.

    GOUT FLARES

    An increase in gout flares is frequently observed upon initiation of anti-hyperuricemic therapy, including treatment with KRYSTEXXA. If a gout flare occurs during treatment, KRYSTEXXA need not be discontinued. Gout flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended starting at least 1 week before initiation of KRYSTEXXA therapy and lasting at least 6 months, unless medically contraindicated or not tolerated.

    CONGESTIVE HEART FAILURE

    KRYSTEXXA has not been studied in patients with congestive heart failure, but some patients in the clinical trials experienced exacerbation. Caution should be exercised when using KRYSTEXXA in patients who have congestive heart failure, and patients should be monitored closely following infusion.

    ADVERSE REACTIONS

    The most commonly reported adverse reactions in clinical trials with KRYSTEXXA were gout flares, infusion reactions, nausea, contusion or ecchymosis, nasopharyngitis, constipation, chest pain, anaphylaxis and vomiting.

    Please see Full Prescribing Information and Medication Guide for more information.

    About TEPEZZA

    INDICATION

    TEPEZZA is indicated for the treatment of Thyroid Eye Disease.

    IMPORTANT SAFETY INFORMATION

    Warnings and Precautions

    Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

    Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

    Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA. Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA.

    Adverse Reactions

    The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache and dry skin.

    For additional information on TEPEZZA, please see Full Prescribing Information at TEPEZZAhcp.com.

    About Horizon

    Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

    Note Regarding Use of Non-GAAP Financial Measures

    EBITDA, or earnings before interest, taxes, depreciation and amortization, and adjusted EBITDA are used and provided by Horizon as non-GAAP financial measures and include adjustments to GAAP figures. These non-GAAP measures are intended to provide additional information on Horizon's performance, operations, expenses, profitability and cash flows. Adjustments to Horizon's GAAP figures as well as EBITDA exclude acquisition and/or divestiture-related expenses, charges related to the discontinuation of ACTIMMUNE development for Friedreich's ataxia, gain or loss from divestiture, gain or loss from sale of assets, upfront, progress and milestone payments related to license and collaboration agreements, litigation settlements, loss on debt extinguishment, costs of debt refinancing, drug manufacturing harmonization costs, restructuring and realignment costs, the income tax effect on pre-tax non-GAAP adjustments and other non-GAAP income tax adjustments, as well as non-cash items such as share-based compensation, depreciation and amortization, non-cash interest expense, long-lived asset impairment charges and other non-cash adjustments. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Horizon maintains an established non-GAAP cost policy that guides the determination of what costs will be excluded in non-GAAP measures. Horizon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon's financial and operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company's estimated 2020 financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators Horizon's management uses for planning and forecasting purposes and measuring the Company's performance. For example, adjusted EBITDA is used by Horizon as one measure of management performance under certain incentive compensation arrangements. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Horizon has not provided a reconciliation of its full-year 2020 adjusted EBITDA estimates to an estimated net income (loss) outlook because certain items such as acquisition/divestiture-related expenses and share-based compensation that are a component of net income (loss) cannot be reasonably estimated due to the significant impact of the variability associated with the size or timing of acquisitions/divestitures and other factors related to Horizon's year-end financial closing process. These components of net income (loss) could significantly impact Horizon's actual net income (loss).

    Forward Looking Statements

    This press release contains forward-looking statements, including, but not limited to, statements related to expected financial performance and operating results, including potential growth in net sales of certain of Horizon's medicines; plans with respect to product development efforts, including planned clinical trials; potential market opportunity for, regulatory approval of and benefits of Horizon's medicines and medicine candidates; and business and other statements that are not historical facts. These forward-looking statements are based on Horizon's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that Horizon's actual future financial and operating results may differ from its expectations or goals; the impacts of the COVID-19 pandemic and actions taken to slow its spread, including impacts on the supply and net sales of Horizon's medicines and potential delays in clinical trials; Horizon's ability to grow net sales from existing medicines and successfully launch new medicines; the availability of coverage and adequate reimbursement and pricing from government and third-party payers; risks relating to Horizon's ability to successfully implement its business strategies; risks inherent in developing novel medicine candidates and existing medicines for new indications; risks associated with regulatory approvals; risks in the ability to recruit, train and retain qualified personnel; competition, including potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon operates and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizon's filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.

    View Full Article Hide Full Article
  2. Horizon Therapeutics plc (NASDAQ:HZNP) today announced that the Company will participate in the 39th Annual J.P. Morgan Healthcare Conference. Tim Walbert, chairman, president and chief executive officer, will present at 11:40 a.m. ET on Jan. 12, 2021.

    The conference presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizontherapeutics.com. A replay of the webcast will be available following the event.

    About Horizon
    Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We…

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced that the Company will participate in the 39th Annual J.P. Morgan Healthcare Conference. Tim Walbert, chairman, president and chief executive officer, will present at 11:40 a.m. ET on Jan. 12, 2021.

    The conference presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizontherapeutics.com. A replay of the webcast will be available following the event.

    About Horizon

    Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

    View Full Article Hide Full Article
  3. - Conference Call Today at 8 a.m. ET -

    Horizon Therapeutics plc (NASDAQ:HZNP) announced that it expects a short-term disruption in TEPEZZA (teprotumumab-trbw) supply as a result of recent government-mandated COVID-19 vaccine production orders related to Operation Warp Speed that have dramatically restricted capacity available for the production of TEPEZZA at its drug product contract manufacturer, Catalent. Operation Warp Speed, per its authority provided through the Defense Production Act of 1950, recently ordered the prioritization of certain COVID-19 vaccine manufacturing at Catalent, resulting in the cancellation of previously guaranteed and contracted TEPEZZA drug product manufacturing slots in December, which were required to maintain…

    - Conference Call Today at 8 a.m. ET -

    Horizon Therapeutics plc (NASDAQ:HZNP) announced that it expects a short-term disruption in TEPEZZA (teprotumumab-trbw) supply as a result of recent government-mandated COVID-19 vaccine production orders related to Operation Warp Speed that have dramatically restricted capacity available for the production of TEPEZZA at its drug product contract manufacturer, Catalent. Operation Warp Speed, per its authority provided through the Defense Production Act of 1950, recently ordered the prioritization of certain COVID-19 vaccine manufacturing at Catalent, resulting in the cancellation of previously guaranteed and contracted TEPEZZA drug product manufacturing slots in December, which were required to maintain TEPEZZA supply. To offset the reduced slots allowed by Operation Warp Speed and Catalent, the Company accelerated plans to increase the production scale of TEPEZZA drug product. The Company currently anticipates that this drug supply shortage will begin at the end of December and could last through the first quarter. The length of the TEPEZZA supply disruption will depend on whether future manufacturing slots are successfully completed as well as decisions by the U.S. Food and Drug Administration (FDA) regarding this increased scale manufacturing process of TEPEZZA. The Company expects to submit data in January from the first increased scale manufacturing lot to the FDA for its review and approval.

    TEPEZZA is a biologic approved for the treatment of Thyroid Eye Disease (TED), which is a rare, serious, progressive and vision-threatening autoimmune disease.1 There are no FDA-approved alternative treatments for TED.

    "We appreciate the efforts Operation Warp Speed and the Administration are taking to accelerate the COVID-19 vaccine production to save lives and put an end to the pandemic," said Tim Walbert, chairman, president and chief executive officer, Horizon. "We understand the impact that the TEPEZZA supply disruption will have on patients with TED and physicians who treat them. Our job is to support these patients and physicians and we will continue to work closely with the FDA and Operation Warp Speed to limit the length of this disruption and accelerate the availability of TEPEZZA drug product supply."

    The Company does not anticipate the short-term supply disruption to impact its full-year 2020 financial guidance, including its previously announced full-year 2020 TEPEZZA guidance of more than $800 million in net sales. The Company expects to have more than $2 billion of cash and cash equivalents at Dec. 31, 2020. The Company also plans to delay the start of its planned TEPEZZA clinical trial in chronic TED and the TEPEZZA exploratory trial in diffuse cutaneous systemic sclerosis until the second quarter of 2021, assuming commercial drug product supplies have normalized by that time. Assuming the chronic TED trial is initiated in the second quarter of 2021, the Company would continue to anticipate data in the first quarter of 2022.

    Consistent with past practice, the Company expects to issue 2021 guidance in connection with its fourth-quarter 2020 earnings call when the Company expects to have additional information regarding TEPEZZA supply.

    Information for patients

    Beginning today, Horizon is delaying new patients starting on TEPEZZA. The Company will be communicating with TEPEZZA patients currently on therapy and the physicians who treat them. The Company's priority will be to resume therapy for those patients as quickly as possible. If patients have additional questions, please contact Horizon Patient Services at 1-833-469-8331.

    Information for healthcare professionals

    Physicians with questions should call 1-866-479-6742 [Option 1] or email .

    Call Information

    At 8 a.m. EST/1 p.m. IST today, the Company will host a live webcast to discuss the TEPEZZA supply disruption. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. A replay of the webcast will be available approximately two hours after the live webcast.

    About TEPEZZA

    INDICATION

    TEPEZZA is indicated for the treatment of Thyroid Eye Disease.

    IMPORTANT SAFETY INFORMATION

    Warnings and Precautions

    Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

    Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

    Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA. Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA.

    Adverse Reactions

    The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache and dry skin.

    For additional information on TEPEZZA, please see Full Prescribing Information at TEPEZZAhcp.com.

    References

    1. Barrio-Barrio J, et al. Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment and Management. Journal of Ophthalmopathy. 2015;2015:1-16.

    Forward-Looking Statements

    This press release contains forward-looking statements, including, but not limited to, statements related to the anticipated impact of recent government orders on TEPEZZA supply, Horizon's financial and operating results, and planned clinical trials; expectations regarding the length of TEPEZZA supply disruptions; Horizon's full-year 2020 financial guidance and guidance with respect to 2020 TEPEZZA sales; Horizon's expected cash position at December 31, 2020; expected financial performance and operating results in future periods; development and commercialization plans; expected timing of clinical trials and results and business and other statements that are not historical facts. These forward-looking statements are based on Horizon's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that further TEPEZZA manufacturing run cancellations, whether as a result of additional government orders or other issues at Horizon's third party manufacturers, or failed manufacturing runs could exacerbate and prolong TEPEZZA supply disruptions; Horizon's actual future financial and operating results may differ from its expectations or goals; Horizon's ability to successfully commercialize and grow net sales from existing medicines, including TEPEZZA; uncertainty regarding the impact of the TEPEZZA supply disruption on TEPEZZA's long-term commercial potential; whether the FDA grants accommodations to alleviate TEPEZZA supply constraints and increase production; impacts of the COVID-19 pandemic and actions taken to slow its spread; risks relating to Horizon's ability to successfully implement its business strategies; risks inherent in developing novel medicine candidates and existing medicines for new indications; risks associated with regulatory approvals; competition, including potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon operates and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizon's filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.

    About Horizon

    Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

    View Full Article Hide Full Article
  4. Horizon Therapeutics plc (NASDAQ:HZNP) today announced that it has provided $500,000 in scholarships to Lake Forest College and created a $500,000 Horizon Therapeutics Endowed Scholarship Fund at Howard University. The scholarships at both institutions will be awarded to economically disadvantaged students and students of color.

    "Equity in education is a significant global issue and we feel it is important for companies and individuals who have the resources to help remove obstacles that exist for marginalized populations," said Tim Walbert, chairman, president and chief executive officer, Horizon. "Financial support is an important step, but in order to make an ongoing impact, it is also our responsibility to provide mentoring, internship…

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced that it has provided $500,000 in scholarships to Lake Forest College and created a $500,000 Horizon Therapeutics Endowed Scholarship Fund at Howard University. The scholarships at both institutions will be awarded to economically disadvantaged students and students of color.

    "Equity in education is a significant global issue and we feel it is important for companies and individuals who have the resources to help remove obstacles that exist for marginalized populations," said Tim Walbert, chairman, president and chief executive officer, Horizon. "Financial support is an important step, but in order to make an ongoing impact, it is also our responsibility to provide mentoring, internship and post-graduate employment opportunities. We look forward to developing long-term partnerships with Lake Forest College, Rosalind Franklin University and Howard University and building a global network of Horizon Scholars."

    At Lake Forest College, two Horizon Scholars will receive four-year, full-ride scholarships to join the Health Professions Program (HPP), which Lake Forest has developed in partnership with Rosalind Franklin University of Medicine and Science. The HPP prepares students for cutting-edge careers in medicine, nursing, pharmacy, physical therapy and the entire range of health professions. Lake Forest faculty members and admission counselors will select the first two Horizon Scholars, who will matriculate in the fall of 2021 as members of the Class of 2025. Selection will be limited to economically disadvantaged first-year students, with preference given to students of color from Lake County or greater Chicago.

    "Thanks to Horizon's generosity, two fortunate students will be able to further their education in the College's Health Professions Program, as well as take advantage of opportunities provided by our partnership with Rosalind Franklin University of Medicine and Science," said Stephen Schutt, president, Lake Forest College. "We have a longstanding commitment to educating students of color and first-generation students, and we are now ranked second in the nation by U.S. News and World Report for our success in this regard. The new Horizon Scholars initiative is a wonderful development for our students and the College."

    The Horizon Therapeutics Endowed Scholarship Fund at Howard University will enable talented young women and men of color in the Chicagoland region to obtain a degree of their choice. Preference will be given to high school students graduating from Horizon's partner school, Perspectives Math and Science Academy located in the Bronzeville neighborhood in Chicago.

    "We are pleased to partner with Horizon Therapeutics on a new endowment that will support Horizon Scholars at Howard," said David P. Bennett, vice president of Development and Alumni Relations. "We believe that student success requires multifaceted support, including access to mentors and internships, which will equip them for future employment. Horizon understands and is committed to providing that support."

    Horizon Scholars at Lake Forest College and Howard University will join the network of 15 existing Horizon Scholars majoring in public health or bioinformatics at the Asian University for Women.

    About Lake Forest College

    Founded in 1857, Lake Forest College is a selective residential, national liberal arts institution located 30 miles north of downtown Chicago. The College has 1,550 students representing nearly every state and 85 countries. Lake Forest has a long tradition of academic excellence and is known for its innovative curriculum and focus on career preparation. For more information, visit lakeforest.edu.

    About Rosalind Franklin University

    Rosalind Franklin University of Medicine and Science is committed to serving humanity through the interprofessional education of health and biomedical professionals and the discovery of knowledge dedicated to improving wellness. Founded in Chicago in 1912, RFU embodies the spirit of inquiry and excellence modeled by its namesake Dr. Rosalind Franklin, whose Photo 51 was crucial to solving the structure of DNA. Recognized for its research in areas including neuroscience, brain-related diseases, inherited disorders, diabetes, obesity, and gait and balance, the university encompasses the Chicago Medical School, College of Health Professions, College of Pharmacy, School of Graduate and Postdoctoral Studies and the Dr. William M. Scholl College of Podiatric Medicine. Learn more at www.rosalindfranklin.edu.

    About Howard University

    Founded in 1867, Howard University is a private, research university that is comprised of 13 schools and colleges. Students pursue studies in more than 120 areas leading to undergraduate, graduate and professional degrees. The University operates with a commitment to Excellence in Truth and Service and has produced one Schwarzman Scholar, three Marshall Scholars, four Rhodes Scholars, 11 Truman Scholars, 25 Pickering Fellows and more than 165 Fulbright recipients. Howard also produces more on-campus African-American Ph.D. recipients than any other university in the United States. For more information on Howard University, visit www.howard.edu.

    About Horizon

    Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

    View Full Article Hide Full Article
  5. Horizon Therapeutics plc (NASDAQ:HZNP) announced today that it has been named to Great Place to Work's 2020 Best Workplaces for Parents list, which highlights companies that have created consistently positive experiences for working parents, especially in light of the COVID-19 pandemic.

    "Horizon is honored to receive this recognition during what has been an unprecedented and difficult year for working parents and caregivers," said Tim Walbert, chairman, president and chief executive officer, Horizon. "As a father, I understand the unique challenges that parents face. Both in ‘normal' times and during the pandemic, our goal is always to offer best-in-class benefits and create progressive programming that supports employees at each phase of…

    Horizon Therapeutics plc (NASDAQ:HZNP) announced today that it has been named to Great Place to Work's 2020 Best Workplaces for Parents list, which highlights companies that have created consistently positive experiences for working parents, especially in light of the COVID-19 pandemic.

    "Horizon is honored to receive this recognition during what has been an unprecedented and difficult year for working parents and caregivers," said Tim Walbert, chairman, president and chief executive officer, Horizon. "As a father, I understand the unique challenges that parents face. Both in ‘normal' times and during the pandemic, our goal is always to offer best-in-class benefits and create progressive programming that supports employees at each phase of their life."

    To aid parents and caregivers throughout the COVID-19 pandemic, Horizon launched an internal virtual community, providing free educational content, tips and ideas for working remotely with children at home. Additionally, the company announced Little Horizons, an onsite childcare center set to open January 2021 on Horizon's Deerfield, Ill. campus for the children of Horizon employees. In response to employee-parent needs during the pandemic, the center will also house the Horizon Study Club, which will provide in-center supervision for school-age children of Horizon employees who are attending school virtually.

    Horizon has a suite of benefits to support working parents. The company provides 10 weeks of paid time off for all birth and adoptive parents, regardless of gender, during parental leave; offers up to $10,000 in adoption support and gives a membership to each employee, providing access to a caregiver database and free back-up care support. Horizon also offers a scholarship fund that provides 25 awards for children of Horizon employees for post-high school education and a Make It Personal account, where employees receive up to $500 to use toward childcare or tutoring expenses.

    Great Place to Work determined the Best Workplaces for Parents list by gathering and analyzing confidential employee experience feedback from U.S. employees across more than 20 industries – the largest annual study of working parents to date. In addition to the Best Workplaces for Parents list, Horizon also ranked as one of the "Best Medium Workplaces," "Best Workplaces in Chicago" and "Best Workplaces in Health Care and Biopharma" by Great Place to Work and FORTUNE this year.

    About Horizon

    Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

    About the Best Workplaces for Parents list

    Great Place to Work based its ranking on a data-driven methodology applied to confidential Trust Index™ survey responses representing over 4.8 million employees working at Great Place to Work-Certified™ organizations. To learn more about Great Place to Work Certification and recognition on Best Workplaces lists published with Fortune, visit greatplacetowork.com.

    About Great Place to Work

    Great Place to Work® is the global authority on workplace culture. They help organizations quantify their culture and produce better business results by creating a high-trust work experience for all employees. They recognize Great Place to Work-Certified™ companies and the Best Workplaces™ in the U.S. Learn more at greatplacetowork.com and on LinkedIn, Twitter and Instagram.

    View Full Article Hide Full Article
View All Horizon Therapeutics Public Limited Company News